drugset / Trial / NCT05233332
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
Non-randomizedSequentialOpen-labelTreatment
Summary
The study consists of the two parts, phase IIa and phase IIb.
Timeline
- Start
- 2022-02-24
- Primary completion
- 2024-01-20
- Completion
- 2024-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | 12 mg | — |
| Subject | Vemurafenib | Small molecule | 720 mg | — |
Indications
No indication recorded.